Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,606.49
(
-0.27%
)
US TECH 100
23,774.80
(
-0.09%
)
Dow Jones
46,021.43
(
-0.44%
)
Brent Oil
104.43
(
-2.02%
)
Bitcoin
70,239.97
(
-1.41%
)
News Focus
News Focus
Post# of 257262
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122802
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: dewophile post# 54404

Tuesday, 11/06/2007 1:50:59 PM

Tuesday, November 06, 2007 1:50:59 PM

Post# of 257262
>MNTA …the FDA contends that it may not be, or else why require immunogenicity studies.<

The FDA has not yet said they will require immunogenicity studies, although they may do that. All they’ve said so far is that they want more information vis-à-vis immunogenicity from all of the generic-Lovenox applicants (Teva, WPI/Amphastar, and Sandoz/MNTA).

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now